BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris CL, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 2020;97:1260-74. [PMID: 32386968 DOI: 10.1016/j.kint.2020.01.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Pepper RJ, Trompeter RS. The causes and consequences of paediatric kidney disease on adult nephrology care. Pediatr Nephrol 2021. [PMID: 34389906 DOI: 10.1007/s00467-021-05182-w] [Reference Citation Analysis]
2 Wang Z, Zhou Z, Zhang Y, Zuo F, Du J, Wang M, Hu M, Sun Y, Wang X, Liu M, Zhang Y, Tang W, Yi F. Diacylglycerol kinase epsilon protects against renal ischemia/reperfusion injury in mice through Krüppel-like factor 15/klotho pathway. Ren Fail 2022;44:902-13. [PMID: 35616094 DOI: 10.1080/0886022X.2022.2079524] [Reference Citation Analysis]
3 Koyun M, Kaya Aksoy G, Çomak E, Özaltın F, Akman S. Outcome of diacylglycerol kinase epsilon-mediated hemolytic uremic syndrome in an infant. Kidney Int 2021;99:1500-1. [PMID: 34023030 DOI: 10.1016/j.kint.2021.02.032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
5 Wong EKS, Marchbank KJ, Lomax-Browne H, Pappworth IY, Denton H, Cooke K, Ward S, McLoughlin AC, Richardson G, Wilson V, Harris CL, Morgan BP, Hakobyan S, McAlinden P, Gale DP, Maxwell H, Christian M, Malcomson R, Goodship THJ, Marks SD, Pickering MC, Kavanagh D, Cook HT, Johnson SA; MPGN/DDD/C3 Glomerulopathy Rare Disease Group and National Study of MPGN/DDD/C3 Glomerulopathy Investigators. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. Clin J Am Soc Nephrol 2021;16:1639-51. [PMID: 34551983 DOI: 10.2215/CJN.00320121] [Reference Citation Analysis]
6 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
7 Alabdulqader M, Alfakeeh K. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC Nephrol 2021;22:140. [PMID: 33879077 DOI: 10.1186/s12882-021-02352-8] [Reference Citation Analysis]
8 Liu D, Ding Q, Dai DF, Padhy B, Nayak MK, Li C, Purvis M, Jin H, Shu C, Chauhan AK, Huang CL, Attanasio M. Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI Insight 2021;6:146959. [PMID: 33986189 DOI: 10.1172/jci.insight.146959] [Reference Citation Analysis]
9 Fu W, Li M, Lin H, Xu Y, Han W, Chen H, Sun L. Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy. Clin Chim Acta 2021;518:78-82. [PMID: 33741360 DOI: 10.1016/j.cca.2021.02.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]